Navigating ISO 10993-1 2026 Updates for Biological Safety

## Navigating ISO 10993-1 Updates: A Risk-Based Approach to Biological Safety With significant updates to the ISO 10993-1 standard on the horizon, medical device manufacturers are re-evaluating their strategies for establishing biological safety. The modern approach, heavily emphasized by regulatory bodies like the FDA, moves beyond a simple test-selection checklist. Instead, it requires a comprehensive Biological Risk Assessment—a systematic process that begins long before any laboratory testing is initiated. This shift requires sponsors to think like toxicologists, focusing first on material composition and potential chemical exposure. To determine the appropriate biological evaluation for a device under these evolving expectations, a sponsor must adopt this risk-based framework. The process starts with thorough material and chemical characterization. Instead of asking, "What tests should we run?", the guiding question becomes, "What is this device made of, and what chemicals could potentially be released during its use?". This foundational data, often including extractables and leachables (E&L) analysis, informs a toxicological risk assessment to determine if any identified chemicals pose an unacceptable risk to patients. This comprehensive evaluation, documented in a Biological Evaluation Plan (BEP) and summarized in a Biological Evaluation Report (BER), forms the cornerstone of a successful regulatory submission. ### Key Points * **Risk Management is Central:** The modern biological evaluation process is not a checklist of tests but a comprehensive risk assessment based on the device's materials, manufacturing processes, and intended use. * **Chemical Characterization First:** Before conducting biological tests, sponsors must thoroughly understand the device's chemical composition. Extractables and Leachables (E&L) testing is a critical first step for many devices. * **Toxicological Risk Assessment is Crucial:** Data from chemical characterization is used to assess the toxicological risk of patient exposure to leached substances. This assessment can often justify forgoing certain biological tests. * **Categorization Drives the Plan:** The nature of body contact (e.g., surface, implant) and the duration of contact (limited, prolonged, permanent) are primary factors in determining the required biological endpoints for evaluation. * **Documentation is Paramount:** The entire process, from planning to final conclusions, must be meticulously documented in a Biological Evaluation Plan (BEP) and a final Biological Evaluation Report (BER). * **Proactive Engagement De-Risks Submissions:** For devices with novel materials, complex manufacturing, or borderline classifications, engaging with the FDA through the Q-Submission program is a valuable strategic tool to gain alignment on the testing plan. --- ### Understanding the Shift to a Risk-Based Approach Historically, many manufacturers approached biocompatibility by following the matrix in ISO 10993-1 as a simple checklist. If a device was a permanent implant, they would conduct the full battery of tests suggested for that category. While straightforward, this approach could lead to unnecessary animal testing, significant expense, and did not always reflect the actual risk profile of the specific device. The updated framework, embraced by both ISO and the FDA, flips this model. It is founded on the principle that biological risk is primarily driven by the chemicals that may be released from a device. Therefore, understanding and controlling those chemicals is the most effective way to ensure patient safety. This risk-based approach requires a holistic evaluation that considers: * All raw materials used in the device. * Chemicals and contaminants from the manufacturing process (e.g., cleaning agents, mold release agents, sterilization residuals). * Degradation products that could form over the device's lifecycle. * The physical characteristics of the device (e.g., surface texture, particle generation). The goal is to build a comprehensive safety profile using all available information, leveraging chemical and physical data to make an informed decision about whether further biological testing is necessary to address any remaining risks. ### A Step-by-Step Guide to the Modern Biological Evaluation Process A robust biological evaluation follows a structured, multi-stage process. Rushing directly to laboratory testing without completing the initial assessment phases is a common and costly mistake. #### Step 1: Develop the Biological Evaluation Plan (BEP) Before any work begins, a formal BEP should be drafted. This living document serves as the roadmap for the entire evaluation. It outlines the strategy, describes the device and its intended use, and provides a scientific rationale for the planned approach. A comprehensive BEP includes: * A detailed description of the device, including all materials and manufacturing processes. * The device's categorization based on the nature and duration of body contact. * A summary of existing data (e.g., material supplier information, literature reviews, testing on similar devices). * An initial risk assessment identifying potential biological hazards. * The proposed plan for chemical characterization and biological testing, with a justification for each step. #### Step 2: Full Material and Chemical Characterization This is the foundation of the risk assessment. Sponsors must gather extensive information about every component and process. The objective is to create a complete chemical inventory of the final, finished device. This involves: * **Material Identification:** Confirming the identity and specifications of all polymers, metals, ceramics, additives, and colorants. * **Process Evaluation:** Identifying all substances used during manufacturing, such as lubricants, solvents, and sterilization agents, that could leave residues. * **Extractables & Leachables (E&L) Testing:** This is a critical step for most devices, especially those with prolonged or permanent patient contact. * **Extractables:** Chemicals that can be forced out of the device under exaggerated laboratory conditions (e.g., aggressive solvents, high temperatures). This represents a worst-case scenario. * **Leachables:** Chemicals that migrate from the device under normal conditions of use. This represents the actual patient exposure profile. #### Step 3: Toxicological Risk Assessment Once the E&L analysis identifies and quantifies the chemicals that could be released from the device, a qualified toxicologist must assess the associated risk. For each identified chemical, the toxicologist will: 1. **Establish a Tolerable Intake (TI):** Determine the maximum daily dose of the substance that is considered safe. This is derived from scientific literature and toxicological databases. 2. **Calculate Patient Exposure:** Estimate the amount of the chemical a patient will be exposed to based on the leachable data. 3. **Calculate the Margin of Safety (MOS):** Compare the tolerable intake to the calculated patient exposure. A sufficiently large margin of safety indicates that the chemical does not pose an unacceptable risk. If all identified chemicals have an adequate margin of safety, it may provide a strong justification for waiving certain biological tests, such as chronic toxicity or carcinogenicity studies. #### Step 4: Gap Analysis and Targeted Biological Testing After the toxicological risk assessment is complete, the sponsor can perform a gap analysis. The initial plan in the BEP is compared against the findings from the chemical characterization and risk assessment. The key question is: "Are there any remaining biological risks that have not been adequately addressed?" Biological testing should be performed only to fill these specific gaps. For example: * If a novel material is used without a history of safe use, irritation or sensitization testing might still be necessary. * If the device has direct blood contact, hemocompatibility testing is generally required regardless of chemical data. * If the toxicological assessment for a specific chemical is inconclusive due to a lack of data, a targeted biological test might be needed to address that uncertainty. #### Step 5: Compile the Biological Evaluation Report (BER) The final step is to consolidate all information into a comprehensive BER. This report summarizes the entire process and presents the final conclusion regarding the biological safety of the device. The BER should clearly link the BEP, the data gathered, the risk assessments, and the final conclusions, demonstrating that all potential risks have been evaluated and mitigated. --- ### Scenario-Based Examples #### Scenario 1: Low-Risk Device (A Reusable Stainless Steel Surgical Instrument) A company is developing a new surgical retractor made from a well-characterized medical-grade stainless steel with a long history of safe use. It only has limited ( < 24 hours) surface contact with intact skin and tissue. * **What Regulators Will Scrutinize:** * Confirmation of the exact alloy and its adherence to industry standards (e.g., ASTM F899). * Detailed information on the manufacturing process, particularly cleaning and passivation steps, to ensure no harmful residues remain. * The potential impact of reprocessing (cleaning and sterilization) on the device surface over its lifetime. * **Critical Data and Evaluation Strategy:** * **Characterization:** The focus is on leveraging existing data. A full E&L study is likely unnecessary. Instead, the sponsor would provide material certifications and a detailed description of the manufacturing and cleaning processes. * **Risk Assessment:** The risk assessment would conclude that the material is well-established, and the potential for chemical leaching is negligible. * **Testing:** Cytotoxicity testing is often still expected as a baseline confirmation. Given the material's history, further *in vivo* tests like irritation or sensitization would likely be unjustified and could be rationalized away in the BER. #### Scenario 2: High-Risk Device (An Implantable Drug-Coated Cardiovascular Stent) A sponsor is developing a novel permanent cardiovascular implant coated with a new polymer designed to elute a drug over several months. * **What Regulators Will Scrutinize:** * The complete chemical profile of the novel polymer, including monomers, oligomers, and cross-linkers. * The degradation profile of the polymer over time and the identity of any degradation byproducts. * The leachable profile of all components: the base metal, the polymer, and the active drug. * The toxicological risk of long-term, systemic exposure to all identified leachables and degradation products. * **Critical Data and Evaluation Strategy:** * **Characterization:** An exhaustive E&L study under simulated-use conditions is mandatory. This will likely involve multiple time points to assess the leaching profile as the polymer degrades. * **Risk Assessment:** A comprehensive toxicological risk assessment for every identified substance is required. This will be a major component of the submission. * **Testing:** Despite extensive chemical data, a significant battery of biological tests will be required due to the high-risk nature of the device. This will include tests for genotoxicity, chronic toxicity, implantation effects (local tissue response), and hemocompatibility. The chemical data informs the testing but does not replace it entirely for such a device. --- ### Strategic Considerations and the Role of Q-Submission The risk-based approach offers flexibility but also introduces complexity and subjectivity. For devices that do not fit neatly into a low-risk or high-risk category, strategic planning is essential. This is particularly true for: * Devices made from novel materials with no history of medical use. * Devices where the sponsor plans to use a risk assessment to justify waiving multiple biological tests that are typically expected. * Combination products where the biological effects of the drug and device must be considered together. In these situations, the FDA's Q-Submission program is an invaluable tool. A pre-submission allows a sponsor to present their proposed Biological Evaluation Plan (BEP) and the rationale behind it to the FDA before committing to expensive, long-term studies. This dialogue can help de-risk the regulatory pathway by gaining early alignment on the proposed testing strategy, ensuring that the plan is sufficient to meet regulatory expectations. Engaging the FDA early can prevent costly delays and requests for additional testing during the final submission review. ### Finding and Comparing Biocompatibility Testing Services Providers Selecting the right laboratory partner is critical for executing a successful biological evaluation. A qualified provider does more than just run tests; they act as a strategic partner who understands the nuances of the risk-based approach. When evaluating potential providers, manufacturers should consider the following: * **Regulatory Compliance:** Ensure the lab operates under Good Laboratory Practice (GLP) as required by regulations like 21 CFR Part 58. * **Analytical and Toxicological Expertise:** Look for integrated services that include not only biological testing but also advanced chemical characterization (E&L) and in-house toxicological risk assessment capabilities. * **Experience:** Seek a provider with a proven track record of testing similar devices and materials. Their experience can help anticipate challenges and interpret complex results. * **Consultative Approach:** A strong partner will review your Biological Evaluation Plan and provide constructive feedback, helping to optimize the testing strategy for both scientific rigor and efficiency. Navigating the landscape of testing labs can be complex. Using a dedicated directory can streamline the process of identifying and vetting qualified partners who meet the specific needs of your device. To find qualified vetted providers [click here](https://cruxi.ai/regulatory-directories/biocompatibility_testing) and request quotes for free. ### Key FDA References * **FDA Guidance: Use of International Standard ISO 10993-1, "Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process"**: This is the primary guidance document outlining the FDA's expectations for a risk-based approach to biocompatibility. * **FDA's Q-Submission Program Guidance**: This document details the process for requesting feedback from the FDA on proposed testing plans and regulatory strategies through a pre-submission meeting. * **21 CFR Part 58 - Good Laboratory Practice for Nonclinical Laboratory Studies**: The regulations governing the conduct of nonclinical safety studies, including most biocompatibility tests. --- This article is for general educational purposes only and is not legal, medical, or regulatory advice. For device-specific questions, sponsors should consult qualified experts and consider engaging FDA via the Q-Submission program. --- *This answer was AI-assisted and reviewed for accuracy by Lo H. Khamis.*